Transformed B-cell Lymphoma : Clonal Evolution, Microenvironment Remodeling and Therapeutic Targets Discovery; Prospective Program (TYPHON-P)

November 13, 2026 updated by: Julien BROSÉUS, Central Hospital, Nancy, France

The progression of small B-cell lymphomas toward a more aggressive histological form, specifically, diffuse large B-cell lymphoma (DLBCL) is a serious and most often fatal event. This process gives rise to several categories of scientific challenges :

  1. Anticipating this transformation through the early detection-while the disease is still in its indolent B-cell lymphoma stage-of biological markers that predict such a shift, particularly those that define tumor sub-clones at high risk of transformation.
  2. Identifying the specific event(s) that, within an ongoing and continuous process, trigger the definitive transition from the indolent B-cell lymphoma phase to the transformed B-cell lymphoma phase.
  3. Identifying the disrupted biological functions that drive treatment resistance in the transformed B-cell lymphoma stage, with the goal of defining new therapeutic targets.

Hypothesis :

  1. The aggressive transformation of indolent B-cell lymphomas results from an imbalance in the subclonal structure, driven by the evolution of a dominant subclone that undergoes aggressive transformation. This subclonal competition-occurring either spontaneously or under therapeutic pressure-is fueled by the acquisition and/or selection of specific molecular and epigenetic alterations, as well as favorable remodeling of the tumor microenvironment. Some of these changes are detectable as early as the indolent phase, offering the prospect of early detection, while others dictate the mechanisms of therapeutic resistance following transformation.
  2. Understanding the mechanisms of therapeutic resistance in transformed DLBCL could pave the way for the development of new, effective treatments. Furthermore, these insights could potentially be applied to resistant forms of de novo DLBCL-the most common category (40%) of B-cell lymphoma.

Our primary objective is to identify and validate the molecular, cellular, and microenvironmental alterations associated with therapeutic resistance in transformed B-cell lymphomas, and to investigate the presence of these mechanisms in resistant forms of de novo DLBCL.

Secondary objective 1. To understand the mechanisms underlying tumor evolution in each subtype of transformed B-cell lymphoma, with regard to both the characteristics of the tumor cell and its microenvironment.

Secondary objective 2. To develop cellular and animal models that mimic the transformed phase of indolent B-cell lymphomas.

Secondary objective 3. To identify biological characteristic, at the indolent B-cell lymphoma stag, that are predictive of aggressive transformation.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

TYPHON-P is a regional, multicenter, longitudinal, and translational observational study based on the prospectivebuilding of a clinical-biological cohort and a centralized biobank, managed by the Lorraine Biological Resource Center and the Pathology Department of the Nancy University Hospital. The study will include patients with indolent B-cell lymphoma, transformed B-cell lymphoma, or de novo aggressive B-cell lymphoma, as well as patients for whom a non-tumor tissue sample is available to serve as a technical reference.

Clinical, biological, therapeutic, and outcome data will be collected from medical records, and residual tissue samples originally obtained for routine clinical care will be processed according to standardized pre-analytical procedures and stored for future analysis.

The program comprises three complementary analytical sub-studies:

(i) a longitudinal, paired study comparing samples from the same patient at both the indolent and transformed stages, with the aim of characterizing the mechanisms of transformation; (ii) an investigation into the association between biological characteristics and therapeutic response within various groups of transformed B-cell lymphomas, with an exploration of whether these associations can be extrapolated to de novo diffuse large B-cell lymphoma (the most common lymphoma subtype, 15% of which exhibit therapeutic resistance); (iii) a prognostic study using samples obtained at the indolent stage to identify biological characteristics associated with the subsequent risk of transformation.

Analyses will be conducted separately for each lymphoma subtype, with Richter transformation and transformed follicular lymphoma serving as the primary models, while rarer forms will be the subject of exploratory analyses. Initial discovery-phase analyses will primarily relie on available retrospective samples. The identified biological findings and signatures will subsequently be evaluated within the prospective collection, following a pre-specified validation strategy. Longitudinal follow-up, planned for a maximum duration of ten years, will serve to document disease transformation, treatments received, therapeutic response, progression, and survival. Prospective samples will undergo standardized processing in a fresh state-including, wherever possible, the preparation of viable cell suspensions-to facilitate multi-omic, single-cell, spatial, and functional analyses, as well as the development of patient-derived models.

Study Type

Observational

Enrollment (Estimated)

710

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

      • Nancy, France, 54000
        • University Hospital of Nancy
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

The objective is to obtain a cohort of approximately 20 to 60 analyzable cases for each subtype of transformed B-cell lymphoma, enabling the exploration of molecular alterations associated with transformation, the study of mechanisms of therapeutic resistance, and the identification of biological signatures with theranostic relevance.

For technical and methodological reasons, a control group consisting of 20 non-tumor lymph node samples will be included in this study.

Recruitment objectives:

Recruitment target for the study group: 210 patients with transformed B-cell lymphoma

Recruitment targets for the 3 control subgroups:

  • 210 patients for the group with untransformed indolent B-cell lymphoma
  • 270 patients for the group with de novo diffuse large B-cell lymphoma
  • 20 patients for the control group

Description

Case groups: transformed B-cell lymphomas

Inclusion Criteria:

Patients who benefited from medical care at the University Hospital of Nancy or the Regional Hospital of Metz

-with a history of, or a current diagnosis of, one of the following five types of indolent B-cell lymphoma: CLL: chronic lymphocytic leukemia FL: follicular lymphoma MZL: marginal zone lymphoma LPL: lymphoplasmacytic lymphoma MCL: mantle cell lymphoma

Patients in whom an aggressive B-cell lymphoma is suspected and for whom a diagnostic workup (including a tumor biopsy with histopathological analysis) is underway:

Richter transformation (RT) Transformed follicular lymphoma (tFL) Transformed marginal zone lymphoma (tMZL) Transformed lymphoplasmacytic lymphoma (tLPL) Blastoid mantle cell lymphoma

  • Cases subsequently confirmed as one of the following histological variants: DLBCL (Diffuse Large B-Cell Lymphoma), Hodgkin lymphoma, or blastoid variant
  • Cases for which biological samples potentially containing tumor cells are available and confirmed to contain a significant proportion of tumor cells (> 30%)
  • Patients for whom at least one of the following types of samples is available:

Circulating blood cells, plasma, serum, any sample of cerebrospinal fluid, pleural fluid, or peritoneal fluid, biopsies performed for the diagnosis and follow-up of the lymphoma, cells extracted from these biopsies

Exclusion Criteria:

  • Samples that do not meet the required diagnostic criteria
  • Samples that do not meet the quality criteria necessary for analysis
  • Samples that lack sufficient tumor content/representativeness for the requirements and analytical standards involved

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: COHORT
  • Time Perspectives: PROSPECTIVE

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Case group : Transformed B-cell lymphoma

Patients :

- who benefited from medical care at the University Hospital of Nancy or the Regional Hospital of Metz

Patients with a history of, or a current diagnosis of, one of the following five types of indolent B-cell lymphoma:

CLL: chronic lymphocytic leukemia FL: follicular lymphoma MZL: marginal zone lymphoma LPL: lymphoplasmacytic lymphoma MCL: mantle cell lymphoma

  • in whom an aggressive B-cell lymphoma is suspected and for whom a diagnostic workup-including a tumor biopsy with histopathological analysis-is currently underway: RT: Richter transformation tFL: transformed follicular Lymphoma tMZL: transformed marginal zone lymphoma tLPL: transformed lymphoplasmacytic lymphoma BL-MCL: blastoid mantle cell lymphoma
  • cases subsequently confirmed as one of the following histological variants: Diffuse large B-cell lymphoma, Hodgkin lymphoma, or a blastoid variant

Identification of molecular and/or cellular signatures associated with the type of treatment response in patients with transformed B-cell lymphoma-categorized as good responders (complete remission), partial responders, and non-responders (progression during treatment or primary refractory disease)-defined in a discovery cohort and subsequently validated in an independent cohort, with an assessment of effect size, reproducibility, and discriminative value.

Performance of biological signatures, measured at the indolent stage, in predicting aggressive histological transformation during follow-up. This analysis will be conducted separately for each homogeneous subgroup of transformed B-cell lymphoma. Biological associations will be characterized by their effect size, their statistical significance-following correction for multiple comparisons-and their reproducibility in a validation cohort.

Presence/absence of these molecular and/or cellular signatures correlated with therapeutic response in de novo DLBCL, and correlation with therapeutic response within this group.

De novo aggressive lymphoma group (primarily de novo DLBCL)

Patients:

- who benefited from medical care at the Nancy University Hospital or the Metz-Thionville Regional Hospital.

Patients in whom a de novo aggressive B-cell lymphoma (DLBCL, Hodgkin lymphoma, or a blastoid variant) is suspected, and for whom a diagnostic workup-including a tumor biopsy with histopathological analysis-is currently underway

  • with no prior history or concurrent diagnosis of a small B-cell lymphoma
  • for whom biological samples are available and confirmed to contain an adequate proportion of tumor cells (> 30%) These samples will be collected either as part of the diagnostic workupor during the course of follow-up

Presence/absence of these molecular and/or cellular signatures correlated with therapeutic response in de novo DLBCL, and correlation with therapeutic response within this group.

Indolent/small-cell non-transformed B-cell lymphomas group

Patients :

  • who benefited from medical care at the Nancy University Hospital or the Metz Regional Hospital
  • presenting with an indolent B-cell lymphoma, still untransformed at the corresponding index date, with a documented follow-up duration at least equal to the time interval between the diagnosis of the indolent lymphoma and the transformation observed in the transformed cases
  • for whom biological samples potentially containing tumor cells are available and contain an adequate proportion of tumor cells (> 30%) These samples will be collected either during the diagnostic work-up or during the course of follow-up

Performance of biological signatures, measured at the indolent stage, in predicting aggressive histological transformation during follow-up. This analysis will be conducted separately for each homogeneous subgroup of transformed B-cell lymphoma. Biological associations will be characterized by their effect size, their statistical significance-following correction for multiple comparisons-and their reproducibility in a validation cohort.

Non-tumor patient" control group / lymph node tissue and blood free of tumor cells

Patients:

  • who benefited from medical care at the Nancy University Hospital or the Metz Regional Hospital
  • for whom one or more blood samples, serous fluid samples, and/or lymph node samples are available (either collected for suspected lymphoma or exploratory purposes, such as sentinel lymph node in solid-tumor oncology)
  • for whom the hypothesis of lymphoma or metastasis of solid cancer has been ruled out based on anatomopathological analysis (non-tumor samples)

Identification of molecular and/or cellular signatures associated with the type of treatment response in patients with transformed B-cell lymphoma-categorized as good responders (complete remission), partial responders, and non-responders (progression during treatment or primary refractory disease)-defined in a discovery cohort and subsequently validated in an independent cohort, with an assessment of effect size, reproducibility, and discriminative value.

Performance of biological signatures, measured at the indolent stage, in predicting aggressive histological transformation during follow-up. This analysis will be conducted separately for each homogeneous subgroup of transformed B-cell lymphoma. Biological associations will be characterized by their effect size, their statistical significance-following correction for multiple comparisons-and their reproducibility in a validation cohort.

Presence/absence of these molecular and/or cellular signatures correlated with therapeutic response in de novo DLBCL, and correlation with therapeutic response within this group.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
To identify and validate the molecular, cellular, and microenvironmental alterations associated with therapeutic resistance in transformed B-cell lymphomas, and to investigate the presence of these mechanisms in resistant forms of *de novo* DLBCLs
Time Frame: 10 years

Outcome measure 1 : correlation between gene expression profiles at agressive stage, and response to treatment.

Measurement : whole transcriptome profiling by RNA-sequencing Unit of measure : transcripts rates Outcome measure 2 : correlation between protein expression profiles at agressive stage, and response to treatment.

Measurement : protein expression by liquid chromatography coupled with mass spectrometry Unit of measure : copy numbers for each protein Outcome measure 3 : correlation between tumor microenvironment, and response to treatment.

Measurement : microenvironment profiling by flow cytometry Unit of measure : comparative enrichment for each immune cell subtype (CD4+ T-cells, CD8+ T-cells, macrophages) Treatment responses : good responders (complete remission), partial responders, and non-responders (progression during treatment or primary refractory disease).

Signatures will be defined in a discovery cohort and subsequently confirmed in an independent cohort.

10 years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Identify, at the indolent/small-cell B-cell lymphoma stage, the biological characteristics that are predictive of aggressive transformation.
Time Frame: 10 years

The analysis will be conducted separately for each homogeneous subgroup of transformed B-cell lymphoma.

Outcome measure 1 : correlation between gene expression profiles at indolent stage, and the occurence of agressive transformation.

Measurement : whole transcriptome profiling Measurement tool : RNA-sequencing Unit of measure : transcripts rates

Outcome measure 2 : correlation between DNA methylation profiles at indolent stage, and the occurence of agressive transformation.

Measurement : whole methylome profiling Measurement tool : long read whole genome sequencing Unit of measure : methylation rates for 28 billion sites

Outcome measure 3 : correlation between proteomic profiles at indolent stage, and the occurence of agressive transformation.

Measurement : protein expression Measurement tool : liquid chromatography coupled with mass spectrometry Unit of measure : absolute numbers for each protein

10 years
Develop cellular and animal models that mimic the transformed phase of indolent B-cell lymphomas.
Time Frame: 10 years

Outcome measure 1 : gene expression profiles concordance between patient-derived experimental models and the original tumors.

Measurement : whole transcriptome profiling by RNA-sequencing Unit of measure : rate of transcripts

Outcome measure 2 : protein expression profiles concordance between patient-derived experimental models and the original tumors.

Measurement : protein expression by liquid chromatography coupled with mass spectrometry Unit of measure : copy numbers for each protein

Outcome measure 3 : tumor microenvironment profiles concordance between patient-derived experimental models and the original tumors.

Measurement : microenvironment profiling by flow cytometry or immunohistochemistry Unit of measure : comparative enrichment for each immune cell subtype (CD4+ T-lymphocytes, CD8+ T-lymphocytes, CD25+ T-lymphocytes, macrophages)

10 years
To understand the mechanisms underlying tumor evolution in each subtype of transformed B-cell lymphoma, with regard to both the characteristics of the tumor cell and its microenvironment.
Time Frame: 10 years

Outcome measure 1 : modification of gene expressions in malignant cells between the indolent stage, and the agressive transformation.

Measurement : gene expression Measurement tool : whole transcriptome sequencing (RNA-seq) Unit of measure : transcripts rates

Outcome measure 2 : modification of protein expressions in malignant cells between the indolent stage, and the agressive transformation.

Measurement : protein expression Measurement tool : liquid chromatography coupled with mass spectrometry Unit of measure : copy numbers for each protein

Outcome measure 3 : modification of tumor microenvironment between the indolent stage, and the agressive transformation.

Measurement : microenvironment profiling Measurement tool : flow cytometry Unit of measure : comparative enrichment for each immune cell subtype (CD4+ T-lymphocytes, CD8+ T-lymphocytes, CD25+ T-lymphocytes, macrophages)

10 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

December 1, 2026

Primary Completion (Estimated)

December 1, 2036

Study Completion (Estimated)

December 1, 2036

Study Registration Dates

First Submitted

November 10, 2026

First Submitted That Met QC Criteria

November 13, 2026

First Posted (Actual)

November 19, 2026

Study Record Updates

Last Update Posted (Actual)

November 19, 2026

Last Update Submitted That Met QC Criteria

November 13, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • 2024PI145

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Anonymized samples and clinical data will be shared with companion research teams.

Material and/or data transfer agreements will be signed between the University hopital of Nancy (promoter) and the associated research teams.

IPD Sharing Time Frame

Start date : inclusion date end date : end of the study (decembre 2036)

IPD Sharing Access Criteria

Material and/or data transfer agreements will be signed between the University hopital of Nancy (promoter) and the associated research teams.

Data will be transfered with secured transfer protocols.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • ICF
  • CSR

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.